FTC warning letters
This article was originally published in The Tan Sheet
The Federal Trade Commission warned 10 Web site operators to either prove or cease making "questionable claims" that their products, including supplements, can prevent, treat or cure H1N1 flu, according to a Nov. 16 release. The commission found the Web sites during a "swine flu surf" that was part of the commission's International Consumer Protection Enforcement Network's 11th Internet Sweep Sept. 21 through Sept. 25. FTC also referred 14 other Web site operators to foreign authorities
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.